DiamiR Biosciences will present three posters at the 2026 Alzheimer's Association International Conference focused on blood-based biomarkers for cognitive decline detection, including plasma APOE genotyping and circulating microRNA signatures. These biomarkers represent a shift toward non-invasive, early-stage identification of neurodegeneration risk before clinical symptoms manifest.
Key Points
- Blood microRNAs predict mild cognitive impairment to Alzheimer's progression
- APOE genotyping now feasible from blood without DNA extraction
- Point-of-care ready approach enables accessible cognitive risk screening
Longevity Analysis
Early detection of cognitive decline through accessible blood biomarkers addresses a critical gap in preventive neurology. The ability to identify individuals transitioning from normal cognition to mild cognitive impairment before irreversible neuronal damage occurs fundamentally changes the timeline for intervention. Rather than waiting for symptomatic decline, circulating brain-enriched microRNAs and APOE genotyping provide measurable signals of neurodegeneration risk, allowing for earlier strategic support of cognitive function and potentially altering disease trajectory through timely lifestyle and clinical intervention.
Original published by LT Wire.